Goldman Sachs
TTPH

Goldman Sachs’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Goldman Sachs’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,010
Closed -$123K – 6174
2018
Q1 		$123K Buy
+2,010
New +$176K ﹤0.01% 5207
2015
Q4 		– Sell
-765
Closed -$114K – 7463
2015
Q3 		$114K Buy
+765
New +$561K ﹤0.01% 6410

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's TTPH Position: Q3 2019 in Review

Goldman Sachs sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 19,049 shares — an estimated $183K sold.

Goldman Sachs first reported a position in TTPH in Q4 2013 and held it in 19 quarters. The position peaked at $2.5M in Q4 2015. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Goldman Sachs reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Goldman Sachs sold 19,049 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $183K.
  • Goldman Sachs first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 19 quarters.
  • Goldman Sachs's Tetraphase Pharmaceuticals, Inc. position peaked at $2.5M in Q4 2015.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.